Versant backs a rebooted Tarveda with $30M round for pipeline development
Just a year after raising $38 million to reboot his company, Tarveda Therapeutics CEO Drew Fromkin has hauled in a $30 million round to fund the second stage of his pipeline building plan.
Fromkin has plenty of ways to spend the money. He’s engaged in a Phase I program for a new lead therapy, PEN-221, a “miniaturized” conjugate targeting somatostatin receptor 2 for small cell lung cancer. And he’s bringing another one of his drugs into the clinic, advancing PEN-866, a miniaturized HSP90-targeting drug conjugate for use in advanced, topoisomerase 1-sensitive cancer patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.